Medicamen Biotech Share Price

    NSE
    401.3
    -5.10 (1.24%)
    MEDICAMEQ • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    -20.86%

    3Y Annualised Return

    -15.23%

    The current prices are delayed, login or Open Demat Account for live prices.

    Medicamen Biotech Stock Performance

    1W Return-3.07
    1Y Return-21.69
    Today's Low400.35
    Prev. Close406.40
    Mkt Cap (Cr.)545.36
    1M Return-7.31
    3Y Return-39.18
    52-Week High630
    Open410.00
    PE Ratio57.78
    6M Return-23.69
    Today's High411.55
    52-Week Low375.05
    Face Value10

    Medicamen Biotech Company background

    Founded in: 1993
    A diversified enterprise, Medicamen Biotech Limited (MBL) is a researchled pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence in 40+ countries. Its offerings include Finished Dosage Forms (FDFs) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough Cold, Cardiovascular Central Nervous System, AntiDiabetic, Gastrointestinal, AntiAllergic among others.The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures NonBetalactum preparations including tablets, capsules, oral liquids and ointments creams.Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.During the year 200607, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.The Company launched the marketing division in Jan09, with 16 products in Delhi Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paidup Equity Shares of Rs.10/ each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) 4,20,000 in 201920. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

    As of 04 Jul, 2025, Medicamen Biotech share price is ₹402.1. The stock opened at ₹410 and had closed at ₹406.4 the previous day. During today’s trading session, Medicamen Biotech share price moved between ₹400.35 and ₹411.55, with an average price for the day of ₹405.95. Over the last 52 weeks, the stock has recorded a low of ₹375.05 and a high of ₹630.00. In terms of performance, Medicamen Biotech share price has declined by 23.7% over the past six months and has declined by 20.86% over the last year.

    Read More
    Medicamen Biotech SIP Return Calculator

    Over the past

    1 year
    3 years

    Total Investment of ₹65,00,000

    Would have become ₹58,64,239 (-9.78%)

    Daily SIP of 25,000 would have become 58,64,239 in 1 year with a gain of -6,35,760 (-9.78%)

    View details of Market Depth

    Medicamen Biotech Fundamental

    Market Cap (in crs)

    545.36

    Face Value

    10

    Turnover (in lacs)

    97.18

    Key Metrics

    Qtr Change %
    36.17% Fall from 52W High
    -19.6
    Dividend yield 1yr %
    Below industry Median
    0.2

    Medicamen Biotech Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Medicamen Biotech Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    29.61 Cr
    45.14 Cr
    44.74 Cr
    43.05 Cr
    47.32 Cr
    Medicamen Biotech Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    168.79 Cr
    181.63 Cr
    143.33 Cr
    117.17 Cr
    113.47 Cr
    127.44 Cr
    Medicamen Biotech Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1.86 Cr
    2.92 Cr
    0.9 Cr
    0.8 Cr
    2.04 Cr
    Medicamen Biotech Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    6.56 Cr
    9.49 Cr
    14.73 Cr
    14.9 Cr
    12.13 Cr
    13.29 Cr

    Medicamen Biotech Result Highlights

    • Medicamen Biotech Ltd reported a 5.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.8%.

    • Its expenses for the quarter were up by 9.2% QoQ and 30.5% YoY.

    • The net profit decreased 30.1% QoQ and decreased 45.9% YoY.

    • The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.6 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Medicamen Biotech

    Promoter
    43.2%
    Foreign Institutions
    0.1%
    Domestic Institutions
    0.8%
    Public
    56%
    Promoter
    43%
    Foreign Institutions
    0.1%
    Domestic Institutions
    0.9%
    Public
    56%
    Promoter
    43%
    Foreign Institutions
    0.1%
    Domestic Institutions
    1.1%
    Public
    55.8%
    Promoter
    43%
    Foreign Institutions
    0.1%
    Domestic Institutions
    1.1%
    Public
    55.8%
    Promoter
    43.2%
    Foreign Institutions
    0.1%
    Domestic Institutions
    1%
    Public
    55.7%
    Promoter
    43.2%
    Foreign Institutions
    0.2%
    Domestic Institutions
    0.7%
    Public
    55.9%

    Medicamen Biotech Technical Analysis

    Moving Averages Analysis
    401.3
    Current Price
    Bullish Moving Averages
    0
    Bearish Moving Averages
    16
    5Day EMA
    406.50
    10Day EMA
    408.70
    12Day EMA
    409.50
    20Day EMA
    412.80
    26Day EMA
    415.60
    50Day EMA
    426.80
    100Day EMA
    444.40
    200Day EMA
    465.30
    5Day SMA
    408.00
    10Day SMA
    408.70
    20Day SMA
    411.50
    30Day SMA
    417.40
    50Day SMA
    424.90
    100Day SMA
    451.50
    150Day SMA
    470.30
    200Day SMA
    479.60
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    17302 Rs
    29445 Rs
    Week Rs
    13210 Rs
    24206 Rs
    Month Rs
    17554 Rs
    30530 Rs
    404.67
    Pivot
    Resistance
    First Resistance
    408.98
    Second Resistance
    415.87
    Third Resistance
    420.18
    Support
    First Support
    397.78
    Second support
    393.47
    Third Support
    386.58
    Relative Strength Index
    39.98
    Money Flow Index
    43.75
    MACD
    -6.12
    MACD Signal
    -6.52
    Average True Range
    14.39
    Average Directional Index
    11
    Rate of Change (21)
    -6.32
    Rate of Change (125)
    -23.28

    Medicamen Biotech Latest News

    30 JUN 2025 | Monday

    Medicamen Biotech Ltd-$ - 531146 - Closure of Trading Window

    03 JUN 2025 | Tuesday

    Medicamen Biotech Ltd-$ - 531146 - Announcement Under Regulation 30 (LODR)- Approval Of Abbreviated New Drug Application (ANDA)

    02 JUN 2025 | Monday

    Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    View More

    Medicamen Biotech Share Price FAQs

    Medicamen Biotech share price is ₹401.3 in NSE and ₹402 in BSE as on 4/7/2025.

    Medicamen Biotech share price in the past 1-year return was -21.69. The Medicamen Biotech share hit a 1-year low of Rs. 375.05 and a 1-year high of Rs. 630.

    The market cap of Medicamen Biotech is Rs. 545.36 Cr. as of 4/7/2025.

    The PE ratios of Medicamen Biotech is 57.78 as of 4/7/2025.

    The PB ratios of Medicamen Biotech is 2.08 as of 4/7/2025

    You can easily buy Medicamen Biotech shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Medicamen Biotech share price is ₹630 and ₹375.05 as of 4/7/2025.

    Please be aware that Medicamen Biotech stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -